These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 10810935)

  • 1. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
    Kreis W; Budman D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
    Friedland D; Cohen J; Miller R; Voloshin M; Gluckman R; Lembersky B; Zidar B; Keating M; Reilly N; Dimitt B
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):19-23. PubMed ID: 10604264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
    Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
    J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel (Taxotere): preclinical and general clinical information.
    Earhart RH
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.